PharmaTher updates FDA new drug application for Ketamine
PharmaTher Holdings (CSE:PHRM) is on track to resubmit information to the U.S. Food and Drug Administration (FDA) by the end of February 2025 ・This resubmission addresses the minor deficiencies ...
PharmaTher receives FDA priority review for ketamine new drug application
Ketamine stock PharmaTher Holdings (CSE:PHRM) has received an amendment acknowledgement letter from the U.S. Food and Drug ...